[go: up one dir, main page]

MX2007000214A - Derivado de tienopirazol que tiene actividad inhibidora de pde 7. - Google Patents

Derivado de tienopirazol que tiene actividad inhibidora de pde 7.

Info

Publication number
MX2007000214A
MX2007000214A MX2007000214A MX2007000214A MX2007000214A MX 2007000214 A MX2007000214 A MX 2007000214A MX 2007000214 A MX2007000214 A MX 2007000214A MX 2007000214 A MX2007000214 A MX 2007000214A MX 2007000214 A MX2007000214 A MX 2007000214A
Authority
MX
Mexico
Prior art keywords
inhibitory activity
derivative
thienopyrazole
pde7 inhibitory
hydrogen
Prior art date
Application number
MX2007000214A
Other languages
English (en)
Inventor
Hidekazu Inoue
Hidenobu Murafuji
Yasuhiro Hayashi
Original Assignee
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd filed Critical Asubio Pharma Co Ltd
Publication of MX2007000214A publication Critical patent/MX2007000214A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion es para proporcionar derivados de tienopirazol que inhiben selectivamente la PDE 7 y, por lo tanto, mejoran el nivel de cAMP celular. Consecuentemente, el compuesto es util para tratar varias clases de enfermedades tales como enfermedades alergicas, enfermedades inflamatorias o enfermedades inmunologicas. El compuesto es un compuesto de tienopirazol representado por la siguiente formula (I) (ver formula (I)): [en donde, especialmente, R1 es un grupo ciclohexilo, un grupo cicloheptilo o un grupo tetrahidropiranilo; R2 es metilo; R3 es un atomo de hidrogeno; y R4 es un grupo: CONR5R6 (en el cual cualquiera de R5 y R6 es un atomo de hidrogeno)].
MX2007000214A 2004-07-01 2005-07-01 Derivado de tienopirazol que tiene actividad inhibidora de pde 7. MX2007000214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004195836 2004-07-01
PCT/JP2005/012208 WO2006004040A1 (ja) 2004-07-01 2005-07-01 Pde7阻害作用を有するチエノピラゾール誘導体

Publications (1)

Publication Number Publication Date
MX2007000214A true MX2007000214A (es) 2007-05-10

Family

ID=35782844

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000214A MX2007000214A (es) 2004-07-01 2005-07-01 Derivado de tienopirazol que tiene actividad inhibidora de pde 7.

Country Status (15)

Country Link
US (3) US7932250B2 (es)
EP (2) EP1775298B1 (es)
JP (3) JP4810426B2 (es)
KR (1) KR101377844B1 (es)
CN (2) CN1976938B (es)
AU (1) AU2005258410B2 (es)
BR (1) BRPI0512916B1 (es)
CA (1) CA2569530C (es)
DK (2) DK2433943T3 (es)
ES (2) ES2407811T3 (es)
MX (1) MX2007000214A (es)
PL (2) PL1775298T3 (es)
PT (1) PT1775298E (es)
RU (1) RU2376309C2 (es)
WO (1) WO2006004040A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418244A (pt) 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
EP2013835B1 (en) 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Preparation of chiral amides and amines
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008005456A2 (en) * 2006-06-30 2008-01-10 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2008026687A1 (en) 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor comprising the derivative
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CN104758291B (zh) * 2007-03-27 2020-03-03 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
CN103936605B (zh) 2007-05-31 2017-09-01 赛诺维信制药公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010101247A1 (ja) 2009-03-05 2010-09-10 塩野義製薬株式会社 Npy y5受容体拮抗作用を有するシクロヘキサン誘導体
ES2660892T3 (es) * 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
IN2012DN02580A (es) * 2009-09-04 2015-08-28 Univ Vanderbilt
KR20130124333A (ko) 2010-11-08 2013-11-13 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
JP2014533258A (ja) * 2011-11-15 2014-12-11 ゼンション・リミテッドXention Limited カリウムチャネル阻害剤としてのチエノ[2,3−c]ピラゾールの使用
SI2846805T1 (sl) * 2012-05-07 2019-04-30 Omeros Corporation Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
FR3000404B1 (fr) 2012-12-28 2015-02-06 Galderma Res & Dev Composition dermatologique comprenant un inhibiteur de pde7 sous forme dispersee, son procede de preparation et son utilisation
FR3000403B1 (fr) * 2012-12-28 2015-02-06 Galderma Res & Dev Composition dermatologique comprenant un inhibiteur de pde7 sous forme solubilisee, son procede de preparation et son utilisation
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AU2018300091B2 (en) 2017-07-12 2023-06-22 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
US11382908B2 (en) 2017-09-26 2022-07-12 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel disease
CN113072562B (zh) * 2021-04-06 2022-01-14 山东大学 一种GSK-3β抑制剂及其制备方法与应用
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance
TW202523670A (zh) * 2023-08-22 2025-06-16 美商歐米諾斯公司 Pde 7調節劑化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649641A (en) 1969-11-04 1972-03-14 American Home Prod 4-hydroxy - 1 - substituted-1h-thieno(2 3-c) pyrazole-5-carboxylic acid derivatives and intermediates thereto
DE2707270A1 (de) * 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
US4248881A (en) * 1979-12-20 1981-02-03 E. R. Squibb & Sons, Inc. Imidazolylethoxymethyl derivatives of pyrazole
AU1595997A (en) 1996-01-26 1997-08-20 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
US6022307A (en) 1998-07-14 2000-02-08 American Cyanamid Company Substituted dibenzothiophenes having antiangiogenic activity
US6627651B1 (en) 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
DE19950647A1 (de) 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
PL360495A1 (en) 2000-05-22 2004-09-06 Aventis Pharmaceuticals Inc. Arylmethylamine derivatives for use as tryptase inhibitors
GB0015095D0 (en) 2000-06-20 2000-08-09 Celltech Chiroscience Ltd Chemical compounds
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
GB0024795D0 (en) * 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
PL361144A1 (en) 2000-11-14 2004-09-20 Altana Pharma Ag (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
EP1688412A3 (en) 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
IL159002A0 (en) 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0122503D0 (en) * 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
IL160990A0 (en) 2001-10-01 2004-08-31 Bristol Myers Squibb Co Spiro-hydantoin compounds useful as anti-inflammatory agents
IL161881A0 (en) 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
CN1264843C (zh) 2001-12-13 2006-07-19 第一阿斯比奥制药株式会社 具有pde7抑制作用的吡唑并嘧啶酮衍生物
CA2484011A1 (en) 2002-05-14 2003-11-27 Axys Pharmaceuticals, Inc. Cysteine protease inhibitors
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
JP2005112840A (ja) * 2003-09-16 2005-04-28 Nissan Chem Ind Ltd 新規ピラゾールスルホニルウレア化合物および除草剤

Also Published As

Publication number Publication date
CN102827082A (zh) 2012-12-19
PL1775298T3 (pl) 2013-08-30
ES2437755T3 (es) 2014-01-14
BRPI0512916A (pt) 2008-04-15
CN1976938B (zh) 2012-08-15
WO2006004040A1 (ja) 2006-01-12
AU2005258410A1 (en) 2006-01-12
KR20070039505A (ko) 2007-04-12
BRPI0512916B1 (pt) 2020-09-15
CA2569530C (en) 2013-07-30
JP5339639B2 (ja) 2013-11-13
US20140073799A1 (en) 2014-03-13
US20110166343A1 (en) 2011-07-07
EP1775298A1 (en) 2007-04-18
EP2433943A1 (en) 2012-03-28
US7932250B2 (en) 2011-04-26
DK2433943T3 (da) 2013-12-16
CN102827082B (zh) 2015-01-07
JP4810426B2 (ja) 2011-11-09
ES2407811T3 (es) 2013-06-14
RU2376309C2 (ru) 2009-12-20
PL2433943T3 (pl) 2014-04-30
CN1976938A (zh) 2007-06-06
JPWO2006004040A1 (ja) 2008-04-24
EP1775298B1 (en) 2013-03-20
KR101377844B1 (ko) 2014-03-25
CA2569530A1 (en) 2006-01-12
US8901315B2 (en) 2014-12-02
JP2011225604A (ja) 2011-11-10
RU2007103815A (ru) 2008-08-10
JP5339638B2 (ja) 2013-11-13
PT1775298E (pt) 2013-06-12
EP2433943B1 (en) 2013-09-11
JP2011225603A (ja) 2011-11-10
DK1775298T3 (da) 2013-05-21
EP1775298A4 (en) 2009-07-01
AU2005258410B2 (en) 2011-12-22
US20090131413A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
MX2007000214A (es) Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MY147181A (en) Prostaglandin derivatives.
WO2008111441A1 (ja) 医薬組成物
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
DE60222931D1 (de) Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
WO2009044788A1 (ja) ベンゾオキサジノン誘導体
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
ATE485258T1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase
TW200503621A (en) Pyrimidine compound and pests controlling composition containing the same
MY136761A (en) Oxazol derivatives
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
NO20071843L (no) Substituerte anilinderivater
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
CR10742A (es) Derivados de piridazina
DK1784404T3 (da) Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
PL350123A1 (en) Tetrahydropyran derivatives and their use as therapeutic agents
EP1921077A4 (en) MEANS FOR THE TREATMENT AND / OR PREVENTION OF SLEEP DISORDERS
MXPA06014536A (es) Indoles utiles en el tratamiento de inflamacion.
ATE420639T1 (de) Antimykotische mittel
EA200901402A1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
WO2008114812A1 (ja) Jak阻害剤

Legal Events

Date Code Title Description
HC Change of company name or juridical status
GB Transfer or rights
FG Grant or registration